Léčba hepatitidy C přímo působícími virostatiky
| Title in English | Therapy of chronic hepatitis C using direct-acting antivirals |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://farmakoterapeutickarevue.cz/cs/lecba-hepatitidy-c-primo-pusobicimi-virostatiky |
| Keywords | viral hepatitis C; Directly Acting Antivirals (DAA); interferon-free therapy |
| Description | Hepatitis C virus (HCV) infection is still a major cause of chronic liver diseases, with approximately 71 million chronically infected persons worldwide. People who inject drugs currently or in the past (PWID), mostly intravenously, are the main risk group among HCV chronically infected persons. The efficacy of therapy with direct-acting antivirals (DAA) is almost 100 %. Currently, the main mission is to diagnose and treat HCV infection in the most possible number of infected persons; it is in collision with poor adherence of PWID in particular. |